---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-124293"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:36:48.059284+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Applied DNA Q4 revenue down 78% to $780K; net loss widens to $3.6M

## Summary
- Total revenues $780K vs $3.6M YoY; COVID testing contract with CUNY canceled in June 2023.
- Gross profit $79K (10% margin) vs $417K (12%) YoY.
- Operating loss $4.2M improved slightly from $4.3M; net loss $3.6M vs $665K YoY.
- Cash and equivalents $7.2M at Sep 30, 2023, down from $10.8M at Jun 30, 2023.
- CEO cites biotherapeutic pivot momentum; GMP capacity expected online H1 2024.

## SEC filing metadata
- accession: 0001104659-23-124293
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/0001104659-23-124293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/tm2332417d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-124293
- JSON: https://secwatch.observer/filing/0001104659-23-124293.json
- Plain text: https://secwatch.observer/filing/0001104659-23-124293.txt

## Key facts
- Earnings Releases
  BNB PLUS CORP. reported fourth quarter ended September 30, 2023 results: revenue approximately $780 thousand, net income $3.6 million.
  - Period: fourth quarter ended September 30, 2023
  - Revenue: approximately $780 thousand
  - Net income: $3.6 million
  - Result: reported results
  source text: in vitro diagnostics, gene editing/therapy and adoptive cell therapy applications.” Summary Fourth Quarter Fiscal 2023 Financial Results: · Total revenues were approximately $780 thousand for the three-month period September 30, 2023, compared to $3.6 million for the same period in the prior fiscal year. The decrease in revenue of approximately $2.8 million was
  evidence_url: https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/0001104659-23-124293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.